Table 2. Susceptibility of mcr 1-positive Escherichia coli isolates to various antimicrobials, Chaco, Bolivia, September–October 2016 (n = 171).
| AMC | PTZ | CAZ | CTX | FEP | MEM | ERT | GEN | CIP | TIG | COL | Total | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % | n | % |
| 72 | 42.1 | 171 | 100 | 130 | 76.0 | 128 | 74.9 | 130 | 76.0 | 171 | 100 | 171 | 100 | 138 | 80.7 | 62 | 36.3 | 171 | 100 | 168 | 1.7 | 171 | 100 |
AMC: amoxicillin/clavulanate (clavulanate at fixed concentration of 4 mg/L); CAZ: ceftazidime; CIP: ciprofloxacin; COL: colistin; CTX: cefotaxime; ERT: ertapenem; FEP: cefepime; GEN: gentamicin; MEM: meropenem; PTZ: piperacillin/tazobactam (tazobactam at fixed concentration of 4 mg/L); TIG: tigecycline.
Numbers and percentages of susceptible isolates are given.